Potential blockbuster drugs to watch in 2023

Top 10 most anticipated drug launches of 2023 - Fierce Pharma

1. Lecanemab ... We start our list much as we did last year, namely with an Alzheimer's disease drug at the top. Eli Lilly's donanemab was ...

25 potential blockbusters to keep an eye on in 2023

In 1986, the ulcer drug Tagamet from Smith, Kline and French (now GSK) emerged as the first blockbusters, generating more than $1 billion in ...

Clarivate Identifies Thirteen Potential Blockbuster Drugs and ...

Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024. Niraparib + abiraterone acetate ...

Potential blockbuster drugs to watch in 2023

Lecanemab and the first potential gene therapy US launch for haemophilia A are two potential blockbuster Drugs to Watch™, says a 2023 ...

10 Potential Blockbuster Drug Approvals in 2023 - Biopharma PEG

Blockbuster Drugs To Be Approved in 2023 · Lecanemab (Eisai/Biogen) · SRP-9001 (Sarepta/ Roche) · Intravitreal Pegcetacoplan (Apellis) · Donanemab ( ...

The Top 10 Most Anticipated Drug Launches of 2023 - NES Fircroft

The Top 10 Most Anticipated Drug Launches of 2023 · Companies: Eisai/Biogen · Companies: Sarepta/Roche Used for: Gene therapy for Duchenne ...

Thirteen potential blockbuster drugs to watch in 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve 'blockbuster' status by 2029 or deliver game-changing ...

Drugs to Watch: 15 Potential Blockbuster Drugs in 2023 - Drug Topics

Read on to learn more about these potential blockbuster medications. Lecanemab (Leqembi) and donanemab. Both lecanemab and donanemab target ...

Seven Potential Blockbuster Approvals To Look Out For In 2023 - Scrip

Related Content · How Biogen's Aduhelm Bet Became A Commercial Bust · Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market · Lilly Waiting On ...

Top 15 Potential Blockbuster Drugs to Watch

Clarivate analysts have identified the treatments they forecast could deliver annual sales of more than $1 billion within five years.

13 Therapies Make Clarivate's 2024 Drugs to Watch List - BioSpace

Some of the drugs on the list, such as AstraZeneca's datopotamab deruxtecan, an antibody drug conjugate, and Johnson & Johnson's talquetamab ( ...

Report Identifies 15 Key Drugs Predicted to Achieve Blockbuster ...

Lecanemab, a next-in-class anti-Aβ, is supported by landmark phase 3 clinical data and received FDA accelerated approval on January 6, 2023.

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual ...

The Drugs to Watch 2023 list from Clarivate primarily features treatments targeted to a particular biomarker, ensuring greater efficacy and less ...

Watch Out For These Potential Best-Seller Drugs In 2023

AstraZeneca created capivasertib (AZD5363) to treat breast cancer. It is a brand-new, highly effective, and selective ATP-competitive pan-AKT kinase inhibitor ...

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual ...

The Drugs to Watch 2023 list from Clarivate primarily features treatments targeted to a particular biomarker, ensuring greater efficacy and less ...

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual ...

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report ... LONDON, Jan. ... Leveraging Clarivate data and insights, ...

Lilly, Biogen and more gear up for blockbuster launches in 2023

With many of the world's top-selling drugs speeding toward patent expirations over the next few years, pharmaceutical companies are hurrying ...

Blockbusters in waiting: Clarivate's drugs to watch in 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in ...

New Blockbuster Drugs to More Than Triple Acute Coronary ...

New Blockbuster Drugs to More Than Triple Acute Coronary Syndrome Treatment Market Value by 2023 ... drugs with “extraordinary blockbuster potential” will ...

At least three oncology 2023 brand launches have blockbuster ...

Other notable 2023 launches include Roche's Columvi, a CD3/CD20 competitor to Epkinly, with $37m; Pfizer's Elrexfio, a CD3/BCMA bispecific for ...